PTN (Palatin Technologies Inc) שווי מצרפי של נכסים

Palatin Technologies (PTN) generates revenue from the sale of melanocortin-based products, including obesity therapies and the drug Vyleesi. The price indicator on the total assets chart is fixed at 5.90. The business relies on distributor success and insurance reimbursements, which determine the model's stability. However, limited pricing power due to strict insurer caps forces the company to apply significant discounts to stimulate sales.

In the women's health biopharmaceutical sector, where Palatin Technologies (PTN) faces a slow commercialization of Vyleesi, the company's financial asset volume—calculated reverse-engineered via ROA as the sum of equity and liabilities—serves as an indicator of its resource base; while growth in this metric signals business expansion, limited funding makes the risk of shareholder dilution critical, rendering the control of borrowing costs essential.